Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3222423 | 0.90 | HDAC8 (0.50) | RAB9ANPC1CYP2C9HDAC8HDAC6 | |
| SCHEMBL10787825 | 0.84 | CYP2C9 (0.48) | RAB9ANPC1CYP2C9HDAC8HDAC6 | |
| SCHEMBL27997984 | 0.84 | CYP2C9 (0.48) | RAB9ANPC1CYP2C9HDAC8HDAC6 | |
| SCHEMBL22816106 | 0.83 | ESR2 (0.57) | RAB9ANPC1CYP2C9HDAC8HDAC6 | |
| SCHEMBL15043523 | 0.83 | NPC1 (0.47) | RAB9ANPC1CYP2C9MAPTLMNA | |
| SCHEMBL14877966 | 0.83 | ESR2 (0.60) | RAB9ANPC1CYP2C9HDAC8HDAC6 | |
| SCHEMBL469036 | 0.82 | HDAC8 (0.61) | RAB9ANPC1CYP2C9HDAC8HDAC6 | |
| SCHEMBL4801277 | 0.82 | NPC1 (0.44) | RAB9ANPC1CYP2C9HDAC8HDAC6 | |
| SCHEMBL12302179 | 0.82 | GSK3B (0.47) | RAB9ANPC1CYP2C9MAPTLMNA | |
| SCHEMBL3219203 | 0.81 | MAPT (0.50) | RAB9ANPC1CYP2C9MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112341320-A | Novel synthesis method of p- (trans-4-hydroxycyclohexyl) phenol | 烟台丰鲁精细化工有限责任公司 | 2021-02-09 | — | — | CN | claimed |
| CN-112341320-A | Novel synthesis method of p- (trans-4-hydroxycyclohexyl) phenol | 烟台丰鲁精细化工有限责任公司 | 2021-02-09 | — | — | CN | disclosed |
| US-9617473-B2 | Switch element comprising a liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-9617473-B2 | Switch element comprising a liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-9120779-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120779-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| EP-2774927-A1 | Inhibitors of HCV NS5A | Presidio Pharmaceuticals, Inc. (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20130155338-A1 | SWITCH ELEMENT COMPRISING A LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-20 | — | — | US | disclosed |
| EP-2423294-A1 | Switch element comprising a liquid-crystalline medium | Merck Patent GmbH (DE) | 2012-02-29 | — | — | EP | disclosed |
| EP-2373168-A1 | INHIBITORS OF HCV NS5A | Presidio Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2010065681-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-7303695-B2 | Process for producing optically active liquid crystalline polymer compound | NIPPON OIL CORPORATION (JP) | 2007-12-04 | — | — | US | disclosed |
| US-7303695-B2 | Process for producing optically active liquid crystalline polymer compound | NIPPON OIL CORPORATION (JP) | 2007-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | MAVS, HAVCR2, EIF2AK2 | RAB9A 1607/4885NPC1 368/4885CYP2C9 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.